1.27p
0.00%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Allergy Therapeutics
Its shares trade on LSE under the ticker AGY.L. It has been listed since 11 October 2004. In the fiscal year to 30 June 2025, it reported revenue of £55.0m and a net loss of £40.1m. At that date it held total assets of £67.5m and shareholders' equity of −£28.2m.
Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex. The company went IPO on 2004-10-11. The firm focuses on the treatment and prevention of allergy with aluminum-free products. The firm's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The firm provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The firm's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. The company uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Oct 2004
- Employees
- 571
- Website
- allergytherapeutics.com ↗
Leadership
Pay as last reported
- Mr. Peter JensenNon-Executive Chairman of the Board£94,000
- Mr. Manuel LlobetChief Executive Officer, Executive Director, since 2009£484,506
- Dr. Shaun FurlongChief Financial Officer, Executive Director, since 2023£92,445
- Mr. Karley CheesmanCompany Secretary
- Mr. Anthony ParkerNon-Executive Director
- Mr. Zheqing ShenNon-Executive Director
- Mr. David BallNon-Executive Independent Director£1,854
- Ms. Cheryl MacdiarmidNon-Executive Independent Director£41,125
- Mr. Tunde OtulanaSenior Non-Executive Independent Director£44,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 29
- Social
- 52
- Governance
- 44
- Direct emissions (scope 1)
- 882 t
- Energy emissions (scope 2)
- 1,174 t
- Value chain emissions (scope 3)
- 1,959 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong research and development capabilities to develop innovative allergy therapeutics.
- Established presence in the global allergy market with a wide range of products.
- Extensive expertise in immunotherapy and allergen manufacturing.
Weaknesses
- Dependency on a limited number of key products for revenue generation.
- Relatively small market share compared to larger pharmaceutical companies.
- Vulnerability to regulatory changes and stringent approval processes for new products.
Opportunities
- Growing demand for allergy therapeutics due to increasing prevalence of allergies.
- Expansion into emerging markets with high potential for growth.
- Potential collaborations with other pharmaceutical companies for product development and distribution.
Threats
- Intense competition from both established pharmaceutical players and emerging biotech companies.
- Stringent regulatory requirements and potential delays in product approvals.
- Economic and political uncertainties affecting healthcare budgets and reimbursement policies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.